FI872801A0 - FOERFARANDE FOER ANVAENDNING AV BAR1 FOER AVSOENDRING AV FRAEMMANDE PROTEINER. - Google Patents

FOERFARANDE FOER ANVAENDNING AV BAR1 FOER AVSOENDRING AV FRAEMMANDE PROTEINER.

Info

Publication number
FI872801A0
FI872801A0 FI872801A FI872801A FI872801A0 FI 872801 A0 FI872801 A0 FI 872801A0 FI 872801 A FI872801 A FI 872801A FI 872801 A FI872801 A FI 872801A FI 872801 A0 FI872801 A0 FI 872801A0
Authority
FI
Finland
Prior art keywords
foer
fraemmande
avsoendring
proteiner
bar1
Prior art date
Application number
FI872801A
Other languages
Finnish (fi)
Other versions
FI872801A (en
Inventor
Vivian L Mackay
Original Assignee
Vivian L Mackay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivian L Mackay filed Critical Vivian L Mackay
Publication of FI872801A0 publication Critical patent/FI872801A0/en
Publication of FI872801A publication Critical patent/FI872801A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FI872801A 1985-10-25 1987-06-24 FOERFARANDE FOER ANVAENDNING AV BAR1 FOER AVSOENDRING AV FRAEMMANDE PROTEINER. FI872801A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79130585A 1985-10-25 1985-10-25
PCT/US1986/002198 WO1987002670A1 (en) 1985-10-25 1986-10-20 Method of using bar1 for secreting foreign proteins

Publications (2)

Publication Number Publication Date
FI872801A0 true FI872801A0 (en) 1987-06-24
FI872801A FI872801A (en) 1987-06-24

Family

ID=25153298

Family Applications (1)

Application Number Title Priority Date Filing Date
FI872801A FI872801A (en) 1985-10-25 1987-06-24 FOERFARANDE FOER ANVAENDNING AV BAR1 FOER AVSOENDRING AV FRAEMMANDE PROTEINER.

Country Status (13)

Country Link
EP (1) EP0243465A1 (en)
JP (1) JP2523562B2 (en)
CN (1) CN1027179C (en)
AU (2) AU6543286A (en)
CA (1) CA1316133C (en)
CZ (1) CZ284251B6 (en)
DK (1) DK320287D0 (en)
FI (1) FI872801A (en)
HU (1) HU206897B (en)
IE (1) IE63822B1 (en)
SK (1) SK279041B6 (en)
UA (1) UA41863C2 (en)
WO (1) WO1987002670A1 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK58285D0 (en) * 1984-05-30 1985-02-08 Novo Industri As PEPTIDES AND MANUFACTURING AND USING THEREOF
AU2334088A (en) * 1987-10-02 1989-05-18 Zymogenetics Inc. Bar1 secretion signal
US5206699A (en) * 1988-05-06 1993-04-27 Gersan Establishment Sensing a narrow frequency band of radiation and gemstones
EP0387319B1 (en) * 1988-07-23 1996-03-06 Delta Biotechnology Limited Secretory leader sequences
WO1991013971A1 (en) * 1990-03-13 1991-09-19 Hawaii Biotechnology Group, Inc. Neurospora expression system
DK82893D0 (en) * 1993-07-08 1993-07-08 Novo Nordisk As PEPTIDE
ATE315083T1 (en) 1995-03-17 2006-02-15 Novozymes As NEW ENDOGLUCANASE
ATE505485T1 (en) 1996-03-01 2011-04-15 Novo Nordisk As APPETITIVE PEPTIDE, COMPOSITION AND USE
HUP0203751A3 (en) 2000-01-10 2005-01-28 Maxygen Holdings Ltd Redwood C G-csf conjugates
DE60138364D1 (en) 2000-02-11 2009-05-28 Bayer Healthcare Llc CLEANING FACTOR VII OR VIIA CONJUGATE
YU48703A (en) 2001-02-27 2006-05-25 Maxygen Aps New interferon beta-like molecules
IL157842A0 (en) 2001-03-22 2004-03-28 Novo Nordisk Healthcare Ag Coagulation factor vii derivatives
US6534059B2 (en) 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
KR20040039444A (en) 2001-09-27 2004-05-10 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Human coagulation factor ⅶ polypeptides
CN1863908B (en) 2003-09-09 2010-08-04 诺和诺德医疗保健公司 Coagulation factor vii polypeptides
BRPI0609079A2 (en) 2005-04-18 2010-11-16 Novo Nordisk As peptide, pharmaceutical composition, method for the treatment of cancer, use of a peptide nucleic acid construct, vector, host, and, antibody
JP5366546B2 (en) 2005-08-16 2013-12-11 ノボ・ノルデイスク・エー／エス Method for producing mature insulin polypeptide
WO2007031559A2 (en) 2005-09-14 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
JP2009528843A (en) 2006-03-06 2009-08-13 ヒューマジーン・インコーポレイテッド Preparation of recombinant human thrombin and fibrinogen
DK2615108T3 (en) 2006-09-08 2017-01-30 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their applications
WO2008037735A1 (en) 2006-09-27 2008-04-03 Novo Nordisk A/S Method for making maturated insulin polypeptides
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
JP5547083B2 (en) 2007-11-20 2014-07-09 アンブルックス，インコーポレイテッド Modified insulin polypeptides and their use
NZ591235A (en) 2008-07-23 2012-07-27 Ambrx Inc Modified bovine g-csf polypeptides comprising non natural amino acid and their uses treating infections such as mastitis
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
US20120107267A1 (en) 2009-03-11 2012-05-03 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
KR101870378B1 (en) 2009-07-17 2018-06-25 릭스하스피탈렛 Masp isoforms as inhibitors of complement activation
US9096843B2 (en) 2009-12-01 2015-08-04 Novo Nordisk A/S Peptidyl α-hydroxyglycine α-amidating lyases
WO2011087808A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
AU2010341518B2 (en) 2009-12-21 2014-01-09 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
JP6148013B2 (en) 2010-03-05 2017-06-14 リグショスピタレト Chimera inhibitor molecule of complement activation
US20110229921A1 (en) 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
WO2011163558A1 (en) 2010-06-25 2011-12-29 Abbott Laboratories Materials and methods for assay of anti-hepatitis c virus (hcv) antibodies
KR101963460B1 (en) 2010-08-17 2019-03-28 암브룩스, 인코포레이티드 Modified relaxin polypeptides and their uses
TWI480288B (en) 2010-09-23 2015-04-11 Lilly Co Eli Formulations for bovine granulocyte colony stimulating factor and variants thereof
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
WO2012076715A1 (en) 2010-12-09 2012-06-14 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
ES2648899T3 (en) 2011-12-09 2018-01-08 Institut Pasteur Multiplex Screening Immunoassay
US8993248B2 (en) 2011-12-31 2015-03-31 Abbott Laboratories Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use
WO2013117705A1 (en) 2012-02-09 2013-08-15 Var2 Pharmaceuticals Aps Targeting of chondroitin sulfate glycans
CN104704118A (en) 2012-10-15 2015-06-10 诺和诺德保健Ag（股份有限公司） Coagulation factor vii polypeptides
JP2014128262A (en) * 2012-11-27 2014-07-10 Kirin Brewery Co Ltd Screening method for yeast strains having conjugative ability
AU2019263303A1 (en) 2018-05-01 2020-12-24 Ambrx, Inc. A method for optimizing antibody expression
US20210278406A1 (en) 2018-07-13 2021-09-09 Varct Diagnostic Aps Isolation of circulating cells of fetal origin using recombinant malaria protein var2csa
CN116948006A (en) 2018-09-11 2023-10-27 北京泰德制药股份有限公司 Interleukin-2polypeptide conjugate and use thereof
US20220009986A1 (en) 2018-10-19 2022-01-13 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
AU2020223031A1 (en) 2019-02-12 2021-08-19 Ambrx, Inc. Compositions containing, methods and uses of antibody-TLR agonist conjugates
CA3174114A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
EP4136459A1 (en) 2020-04-13 2023-02-22 Abbott Laboratories Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample
KR20230042301A (en) 2020-08-04 2023-03-28 애벗트 라보라토리이즈 Improved methods and kits for detecting SARS-COV-2 proteins in samples
JP2023538071A (en) 2020-08-20 2023-09-06 アンブルックス，インコーポレイテッド Antibody-TLR agonist conjugates, methods and uses thereof
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
JP2024512775A (en) 2021-04-03 2024-03-19 アンブルックス，インコーポレイテッド Anti-HER2 antibody drug conjugate and its use
CN115806889B (en) * 2022-09-28 2024-06-11 山东大学 Saccharomyces cerevisiae engineering bacteria for improving gene expression level and construction method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4613572A (en) * 1983-08-15 1986-09-23 Kansas State University Research Foundation Yeast BAR1 gene plasmid
JPS61247384A (en) * 1984-10-18 1986-11-04 チモ−ジエネテイツクス　インコ−ポレ−テツド Development of plasminogen activating factor in yeast
DE3537176C2 (en) * 1984-10-18 1994-06-09 Zymogenetics Inc Tissue plasminogen activator and process for its manufacture

Also Published As

Publication number Publication date
CZ776486A3 (en) 1996-09-11
HUT43624A (en) 1987-11-30
WO1987002670A1 (en) 1987-05-07
JPS63501614A (en) 1988-06-23
AU7400391A (en) 1991-07-18
UA41863C2 (en) 2001-10-15
SK776486A3 (en) 1998-06-03
DK320287A (en) 1987-06-23
SK279041B6 (en) 1998-06-03
AU676132B2 (en) 1997-03-06
JP2523562B2 (en) 1996-08-14
CN86107554A (en) 1987-08-26
CZ284251B6 (en) 1998-10-14
CA1316133C (en) 1993-04-13
AU6543286A (en) 1987-05-19
DK320287D0 (en) 1987-06-23
FI872801A (en) 1987-06-24
CN1027179C (en) 1994-12-28
IE63822B1 (en) 1995-06-14
EP0243465A1 (en) 1987-11-04
HU206897B (en) 1993-01-28
IE862804L (en) 1987-04-25

Similar Documents

Publication Publication Date Title
FI872801A0 (en) FOERFARANDE FOER ANVAENDNING AV BAR1 FOER AVSOENDRING AV FRAEMMANDE PROTEINER.
FI850004A0 (en) FOERFARANDE FOER IDENTIFIERING AV NUKLEINSYROR.
FI850090A0 (en) FOERFARANDE FOER FRAMSTAELLNING AV NATURSTENSIMITATIONER.
FI850605A (en) FOERFARANDE FOER FRAMSTAELLNING AV FORMAR.
FI850951L (en) FOERFARANDE FOER FRAMSTAELLNING AV KISEL.
FI860957A0 (en) FOERFARANDE FOER FOERSNABBANDE AV FIXERINGEN AV KROMATHALTIGA TRAESKYDDSSALTER.
FI850208L (en) FOERFARANDE FOER STYRNING AV ALKALISKA CELLULOSAKOK.
FI850686A0 (en) FOERFARANDE FOER FRAMSTAELLNING AV EN FLYGSKAERM.
FI850864A0 (en) FOERFARANDE FOER FRAMSTAELLNING AV RIBONUCLEINSYRA.
FI850379A0 (en) BEKAEMPNING AV MICROBER.
FI850660A0 (en) FOERFARANDE FOER FRAMSTAELLNING AV 3-ARYLOXI-3-PHENYLPROPYLAMIN.
FI850353A0 (en) AENDSPONT FOER KANTSTOED AV BETONG.
FI850876L (en) FOERFARANDE FOER EMBALLERING AV PAPPERSRULLAR.
FI850931A0 (en) FOERFARANDE FOER TILLVARATAGANDE AV VATTNETS TILLFRYSNINGSVAERME.
FI850399A0 (en) UPPVAERMBART VERKTYG FOER UPPHETTNING AV ROERFOERBINDNINGSSTYCKEN.
FI850120L (en) AUTOMATISERINGSMETOD AV GLASBOEJNINGSUNG.
FI850937A0 (en) FOERFARANDE FOER FRAMSTAELLNING AV TRAESKIVOR.
FI850333A0 (en) ANVAENDNING AV TORVASKA.
FI850420A0 (en) FOERFARANDE FOER MAETNING AV FJAERRVAERMEFOERBRUKNING.
FI850683L (en) ANORDNING FOER KORSMAETNING AV FORDON.
FI862165A (en) FOERFARANDE FOER IMPREGNERING AV VATTENAVVISANDE PAPPER.
FI850102A0 (en) STOEDANORDNING FOER UPPOEVNINGSANLAEGGNING AV EN OEGON-HAND-KOORDINATION.
FI850952A0 (en) FOERPACKNING AV JAEST FOER BAKNINGSAENDAMAOL.
FI850625A0 (en) FOERFARANDE FOER REGLERING AV AVLAEGSNANDE AV KONDENSAT FRAON EN PAPPERSMASKINS TORKPARTI.
FI850059A0 (en) FOERFARANDE FOER FRAMSTAELLNING AV EN HYLSA.

Legal Events

Date Code Title Description
FD Application lapsed
FD Application lapsed

Owner name: ZYMOGENETICS, INC.